Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 18;4(2):53-60.
doi: 10.14744/hf.2022.2022.0048. eCollection 2023 Mar.

Evaluation of the effectiveness of drug-eluting transarterial chemoebolization in hepatocellular carcinoma

Aydan Mutis Alan  1 , Ozkan Alan  2   3 , Ruslan Asadov  4 , Coskun Ozer Demirtas  5 , Haluk Tarik Kani  5 , Perran Fulden Yumuk  2   3 , Osman Cavit Ozdogan  5 , Feyyaz Baltacioglu  4 , Feyza Gunduz  5
Affiliations

Evaluation of the effectiveness of drug-eluting transarterial chemoebolization in hepatocellular carcinoma

Aydan Mutis Alan et al. Hepatol Forum. .

Abstract

Background and aim: Transarterial Chemoembolization (TACE) therapy is currently considered as first option therapy in the intermediate stage HCC. The purpose of our study is to assess the efficacy and prognostic factors related to the DEB- TACE therapy.

Materials and methods: The data from 133 patients with unresecetable HCC who were treated with DEB-TACE and followed between January 2011-March 2018 were retrospectively evaluated. To assess the efficacy of therapy, control imagings were performed at 30th and 90th days after the procedure. Response rates, survival outcomes, and prognostic factors were investigated.

Results: According to the Barcelona staging system, 16 patients (13%) were in the early stage, 58 patients (48%) were in the intermediate stage and 48 patients (39%) were in the advanced stage. There were complete response (CR) in 20 patients (17%), partial response (PR) in 36 patients (32%), stable disease (SD) in 24 patients (21%) and progressed disease (PD) in 35 (30%) patients. Median follow-up time was 14 months (range 1-77 months). Median PFS and OS were 4 months and 11 months, respectively. In multivariate analysis, posttreatment AFP ≥400 ng/ml was found to be an independent prognostic factor on both PFS and OS. Child-Pugh classification and tumor size >7 cm were independent prognostic factors on OS.

Conclusion: DEB-TACE is effective and a tolerable treatment method for unresectable HCC patients.

Keywords: DEB-TACE; Hepatocellular carcinoma; Prognostic factors Presented as oral presentation at 12th National Hepatology Congress in Turkiye in 2019.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Survival outcomes for whole cohort by Kaplan-meir graphic. (a) Progression-free survival graphic. (b) Overall survival graphic
Figure 2
Figure 2
Survival outcomes according to barcelona stage and child-pugh classification by kaplan meier graphic. (a) progression-free survival graphic for Barcelona stage system. (b) Progression-free survival graphic for child-pugh classification. (c) Overall survival graphic for barcelona stage system. (d) Overall survival graphic for child-pugh classification.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE. Cancer statistics 2021. CA Cancer J Clin. 2021;71(1):7–33. - PubMed
    1. Amit S, Jorge A M. Screening for hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2008;4(3):201–208. - PMC - PubMed
    1. European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. - PubMed
    1. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol. 1993;4(6):741–747. - PubMed
    1. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. - PubMed

LinkOut - more resources